Everything below concerns quality control. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-01-08. Where a claim depends on a specific study, the study is described rather than over-claimed.
The full name often given is N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. This name indicates a chain containing tyrosine, isoleucine, and a six-carbon amino acid derivative. Databases list a CAS Registry Number and a molecular formula for the compound. The peptide is small compared with proteins, and its structure allows it to be studied in cell cultures and animal models. Exact identity depends on the supplier's synthesis and purification process. Minor impurities can remain after synthesis.
Chemically, dihexa belongs to a broader group of angiotensin IV analogs. Researchers have modified the natural peptide to alter stability, binding, or distribution. Such changes can affect how the molecule behaves in experiments. The parent peptide angiotensin IV is involved in various physiological processes, but the modified analog is not identical to it. Public summaries sometimes blur the distinction between the natural fragment and the synthetic research compound. This distinction matters when interpreting study results.
Regulatory and commercial contexts differ from clinical medicine. Dihexa is not approved as a drug by major agencies, and no published human trials establish its safety or efficacy. It is often sold as a research chemical labeled for laboratory use only. Suppliers may provide certificates of analysis, but purity and identity depend on the specific batch. Legal status varies by country and may treat such compounds as unapproved substances for human consumption.
Dihexa is a synthetic peptidomimetic derived from angiotensin IV, a naturally occurring peptide fragment. It was created as a research compound to explore central nervous system signaling rather than as an approved therapeutic. Early work described it as a small, orally available molecule in rodent studies. Its structure combines tyrosine, isoleucine, and aminohexanoic acid components with a hexanoic acid cap. The compound is commonly referred to by the research code PNB-0408.
| Property | Value | Notes |
|---|---|---|
| Common name | Dihexa | Shorthand used in research literature and supplier catalogs. |
| CAS Registry Number | 1401708-83-5 | Identifier assigned to the synthetic peptide. |
| Molecular formula | C27H44N4O5 | Reported formula; verify with a certificate of analysis. |
| Appearance | White to off-white powder | Typical form for lyophilized research peptides. |
| Typical storage | −20 °C or below, desiccated | Common condition for peptide stability. |
Discussion of dihexa in online communities sometimes outpaces the scientific record. Anecdotal reports are difficult to verify and may not distinguish effects from placebo or expectation. The absence of approved human data means long-term risks remain unknown. Researchers continue to investigate related compounds and pathways. Open questions include whether animal findings translate to humans and which biological targets matter most. No consensus exists on these points. Current reviews emphasize the need for rigorous clinical research.
Most published work on dihexa consists of preclinical studies using cell cultures or rodents. Reports have described effects on synaptic connectivity and performance on cognitive tasks in some animal models. These findings are generally presented as preliminary and require independent replication. Study designs, doses, and outcome measures vary across experiments, which complicates direct comparison. No large controlled human trials have established efficacy or safety for any medical use. At present, the evidence base is limited.
Human data for dihexa remain absent from peer-reviewed clinical literature. As a result, questions about absorption, distribution, metabolism, excretion, and long-term safety are unresolved. Discussions often appear in nootropic forums, where anecdotal reports cannot substitute for controlled trials. Researchers have called for more rigorous pharmacokinetic and toxicological studies before any clinical evaluation. Until such data exist, dihexa is best described as an investigational research compound rather than a proven intervention.
The proposed mechanism for dihexa centers on hepatocyte growth factor, or HGF, and its receptor c-Met. HGF signaling is involved in cell growth, survival, and synapse formation. Dihexa has been described as an HGF mimetic or modulator in preclinical literature. Whether it binds c-Met directly, increases HGF availability, or acts through another route remains uncertain. This mechanistic uncertainty is a recurring theme in reviews of the compound, and no single molecular model has been confirmed across independent laboratories.
Research on dihexa has primarily used rodent models and cultured cells. Common endpoints include dendritic spine density, synaptic protein expression, and performance on maze or avoidance tasks. Some studies report improvements in cognitive measures after scopolamine-induced deficits or in aged animals. These findings are interesting but come from a small body of work, and independent laboratories have not consistently replicated all reported effects. Larger, preregistered studies would help clarify which results are robust.
The compound originated from work on angiotensin IV, a peptide fragment of the renin-angiotensin system. Researchers modified angiotensin IV-related structures to produce molecules with altered stability and activity. Dihexa emerged from that effort and was reported to promote dendritic spine growth in cultured neurons. Some studies link its effects to hepatocyte growth factor signaling and the c-Met receptor, while other work points to insulin-regulated aminopeptidase. The precise primary target remains a subject of investigation, and findings may depend on cell type, assay conditions, and species.
In animal research, dihexa has been administered through several routes, and reports describe improved performance on spatial learning and memory tasks in rodents. These results are frequently cited in discussions of nootropic compounds. However, species differences, small sample sizes, and varied testing protocols limit how far the findings can be generalized. No large randomized controlled trials in humans have established efficacy or long-term safety. Claims about human cognitive enhancement therefore remain speculative, and the compound is best described as an experimental laboratory substance rather than a proven therapeutic or supplement.
Dihexa is a synthetic compound studied in laboratory and animal models for effects on synaptic connectivity and cognitive performance. It is often described as a peptide analog because its structure incorporates amino acid residues linked to a hexanoic acid group. The molecule is not a naturally occurring human hormone or neurotransmitter. Its name appears in research literature and online discussions, but it has not been approved as a medicine by major regulatory agencies. Most information comes from preclinical experiments rather than controlled human trials.
=== Indonesia === The Just and Prosperous People's Party of the Advanced Indonesia Coalition condemned the U.S. strikes in Venezuela and denounced it as "vulgar aggression". The National Awakening Party of the Advanced Indonesia Coalition, through its faction in the House of Representatives condemned the U.S. strikes and accused Donald Trump of using the "law of the jungle" which can be set by other advanced, developed powers to force developing states into capitulation, leading to "modern-era imperialism and colonization". The Prosperous Justice Party through its faction in the House of Representatives condemned the U.S. strikes as an illegal act against the legitimate Venezuelan government and warned that this can set a precedence for future illegal acts committed by a powerful ruling government of a state against the government of their rival states or neighboring states.
=== Angiogenesis === Angiogenesis is an essential aspect of tumour development. In order for a tumour to grow and significantly increase in size, it must have a sufficient blood supply. If the tumour is unable to develop the blood supply it requires, cells within the tumour will begin to die and further growth will be halted. Angiogenic factors such as vascular endothelial growth factor (VEGF), stromal cell-derived factor 1 (SDF-1), fibroblast growth factor (FGF) and platelet-derived growth factor (PDGF) are expressed by CAF to encourage the growth of new blood vessels. Some of these factors may also recruit cells that are vital to the angiogenic process, for instance SDF-1 attracts bone-marrow derived endothelial cells.
=== Aliases === 5-Methyltetrahydrofolate-Homocysteine Methyltransferase Reductase MSR [Methionine Synthase]- Cobalamin Methyltransferase (Cob(II)Alamin Reducing) Methionine Synthase Reductase, Mitochondrial EC 1.16.1.8 CblE
Baculovirus-infected insect cells (Sf9, Sf21, High Five strains) or mammalian cells (HeLa, HEK 293) allow production of glycosylated or membrane proteins that cannot be produced using fungal or bacterial systems. It is useful for production of proteins in high quantity. Genes are not expressed continuously because infected host cells eventually lyse and die during each infection cycle.
=== GDGT-0 === GDGT-0 has zero cyclopentane moieties and is the most ubiquitous isoGDGT synthesized by archaea. Halophilic archaea are the only group of archaea not known to produce GDGT-0. Carbon isotope analyses and association with sites of anaerobic methane oxidation suggest that GDGT-0 is produced via methanotrophs. In microbiology literature not dealing with the geological record, GDGT-0 is sometimes referred to as caldarchaeol.
Sources: en.wikipedia.org
On 5 January 2026, the Venezuelan government issued an emergency order to police to arrest anyone who supported the US attack and mobilized colectivos (pro-government paramilitaries) who established roadblocks and searched cars and people. Fourteen journalists were detained, but 13 of them were later released. On 6 January, gunfire broke out in Caracas as the ministry of communication announced that police fired upon one of their own military drones "flying without permission" but that the drone suffered no damage.
Methanediamine is the simplest geminal diamine. Its chemical formula is CH2(NH2)2, and its structure consists of two amino groups on a central carbon atom. Although methanediamine only exists transiently in solution, its hydrochloride salt has been used in chemical synthesis since 1914. The hydrochloride is useful for the synthesis of primary amides from amino acids.
=== Schizophrenia === Persistent KOR signaling has been implicated in the pathophysiology of schizophrenia, in the generation of both positive and negative symptoms, and as an explanation for treatment-resistant psychosis. Mechanistically, chronic KOR activation produces long-term sensitization of dopamine D2 receptors in the striatum, which manifests as supersensitized D2 receptor states that amplify phasic dopamine signaling and hyperresponsivity to dopaminergic stimuli. This mechanism could interact with the underlying excessive striatal dopamine transmission in schizophrenia, potentiating positive symptoms including delusions and hallucinations, and explaining why dopamine D2 receptor antagonists (antipsychotics) remain effective. Apart from striatal mechanisms, KOR signaling modulates cortical glutamate and GABA homeostasis through KOR activation on GABAergic terminals of dynorphin-expressing neurons in prefrontal cortex which suppresses GABA release and disrupting the balance of cortical inhibition-excitation that might drive cognitive dysfunction and negative symptoms. Thus, KOR antagonism may provide a complementary strategy to D2 antagonism by simultaneously reducing D2 receptor sensitization to normalize striatal dopamine responsivity and restoring cortical inhibition-excitation balance to ameliorate cognitive dysfunction. The receptor availability also predicts severity of anhedonia in schizophrenia.
MR-2034, or Mr-2034, also known as (–)-MR-2033, is a selective κ-opioid receptor (KOR) agonist of the benzomorphan family. Unlike other benzomorphan KOR agonists like cyclazocine and alazocine, MR-2034 does not also act on sigma receptors. In addition to the KOR, it has affinity for the μ-opioid receptor (MOR), but does not activate this receptor. The drug produces dose-dependent hallucinogenic and dysphoric effects in humans, as well as other effects such as dizziness, anxiety, and sedation. These effects can be blocked by the non-selective opioid receptor antagonist naloxone. The preceding findings led to the conclusion that the hallucinogenic and dysphoric effects of benzomorphans are mediated by the KOR rather than by sigma receptors. MR-2034 was first described in the scientific literature by 1975 and its hallucinogenic effects in humans were described in 1986.
== Definition of the resonant frequency == An ion in a static and uniform magnetic field will move in a circle due to the Lorentz force. The angular frequency of this cyclotron motion for a given magnetic field strength B is given by
Sources: en.wikipedia.org
Sometimes distinct from the modern periods themselves, the terms "modernity" and "modernism" refer to a new way of thinking, distinct from previous ways of thinking such as medieval thinking. "Postmodernism", coined in 1949, describes a movement in art rather than a period of history, and is usually applied to arts, but not to any events of recent history. This changed, when postmodernity was coined to describe major changes in the 1960s in economy, society, culture, and philosophy. These terms stem from European history. In worldwide usage, such as in China, India, and Islam, the terms are applied in a different way, but often in the context with their contact with European culture in the Age of Discovery.
During the First World War (1914–1918), and for a short period afterwards, there were at least 250 recognised airfields in France that the Royal Flying Corps, Royal Naval Air Service, and Royal Air Force used at various times.
A presentation seen during gameplay reveals that GLaDOS was included in a proposed bid for de-icing fuel lines, incorporated as a fully functional disk-operation system that is arguably alive, unlike Black Mesa's proposal, which inhibits ice, nothing more. After contracting a terminal illness from moon rocks used in portal experiments, Cave decides to attempt to back up his consciousness to a computer. He realises that the technology will not be ready in time to backup his brain due to his imminent demise, and leaves instructions to forcefully backup the consciousness of his assistant Caroline. Upon being uploaded to GLaDOS, Caroline attempts to kill every scientist in the building in under a fraction of a second. After extensive attempts to control her with smaller robots called personality spheres that would act as emotional limits and a sort of artificial "conscience", GLaDOS managed to eventually convince the scientists that she was primarily concerned with science and requested a lethal brain neurotoxin for an experiment about cats. GLaDOS initiated the experiment during the company's first annual bring-your-daughter-to-work day in 1998. Immediately after activation, the facility was flooded with deadly neurotoxin by the AI. Events of the first Half-Life game occur shortly after that, presumably leaving the facility forgotten by the outside world due to apocalyptic happenings. Wolpaw, in describing the ending of Portal 2, affirmed that the Combine invasion, chronologically taking place after Half-Life and before Half-Life 2, had occurred before Portal 2's events.
Relugolix is a selective antagonist of the gonadotropin-releasing hormone receptor (GnRHR), with a half-maximal inhibitory concentration (IC50) of 0.12 nM. A dosage of relugolix of 40 mg once per day has been found to suppress estradiol levels to postmenopausal levels (<20 pg/mL) within 24 hours in premenopausal women. In the control group of women, estradiol levels fluctuated between 50 and 250 pg/mL. Estradiol levels have been found to return to normal concentrations within 4 weeks of discontinuation of relugolix in premenopausal women. The medication additionally suppresses levels of progesterone, luteinizing hormone, and follicle-stimulating hormone in premenopausal women. Relugolix at a dosage of 40 mg or more once per day has been found to reduce testosterone levels to sustained castrate levels (<20 ng/dL) in men. It additionally suppresses luteinizing hormone and follicle-stimulating hormone levels in men. Lower doses of relugolix (<40 mg/day) are under investigation for achieving partial sex hormone suppression in the treatment of endometriosis and uterine fibroids. This is intended to reduce the incidence and severity of menopausal symptoms such as hot flushes and decreased bone mineral density that are secondary to estrogen deficiency.
=== Removal and suspension === As per Art. 317, the chairman or any other member of a Public Service Commission shall only be removed from their office by order of the president on the ground of "misbehavior" after the Supreme Court, on a reference being made to it by the president, has, on inquiry, reported that the chairman or such other member ought to be removed. The president may suspend the chairman or other members of the commission until the report of the Supreme Court is received.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide modeled on angiotensin IV. It is used in laboratory and animal research, not as an approved medicine. Human effects remain poorly characterized.
It is produced by chemical synthesis, not extracted from plants or animals. Its design is based on a naturally occurring peptide fragment. Suppliers sell it as a research chemical.
No, dihexa is a modified analog of angiotensin IV. The two share a structural relationship but differ in chemical details. Research on one does not automatically apply to the other.
Dihexa is a synthetic peptidomimetic related to angiotensin IV. It is studied in preclinical research for effects on synaptic signaling and cognition. It is not an approved medication.